CO2023006808A2 - Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados - Google Patents
Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuteradosInfo
- Publication number
- CO2023006808A2 CO2023006808A2 CONC2023/0006808A CO2023006808A CO2023006808A2 CO 2023006808 A2 CO2023006808 A2 CO 2023006808A2 CO 2023006808 A CO2023006808 A CO 2023006808A CO 2023006808 A2 CO2023006808 A2 CO 2023006808A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- hair loss
- deuterated
- regimens
- loss disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106790P | 2020-10-28 | 2020-10-28 | |
| US202163155637P | 2021-03-02 | 2021-03-02 | |
| PCT/US2021/057123 WO2022094133A1 (en) | 2020-10-28 | 2021-10-28 | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023006808A2 true CO2023006808A2 (es) | 2023-09-08 |
Family
ID=78725692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0006808A CO2023006808A2 (es) | 2020-10-28 | 2023-05-25 | Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230390292A1 (https=) |
| EP (1) | EP4236956A1 (https=) |
| JP (1) | JP2023553253A (https=) |
| KR (1) | KR20230093504A (https=) |
| AU (1) | AU2021372512A1 (https=) |
| CA (1) | CA3196551A1 (https=) |
| CL (1) | CL2023001201A1 (https=) |
| CO (1) | CO2023006808A2 (https=) |
| DO (1) | DOP2023000085A (https=) |
| IL (1) | IL302401A (https=) |
| JO (1) | JOP20230090A1 (https=) |
| MX (1) | MX2023005027A (https=) |
| PE (1) | PE20231945A1 (https=) |
| WO (1) | WO2022094133A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3250876A1 (en) * | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | DOSAGE REGIMEN FOR TREATMENT WITH DEUTERATED JAK INHIBITORS |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| US12247034B1 (en) * | 2024-04-19 | 2025-03-11 | Sun Pharmaceutical Industries, Inc. | Crystalline form of deuruxolitinib phosphate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| CN1255185C (zh) | 2001-05-03 | 2006-05-10 | 弗·哈夫曼-拉罗切有限公司 | 无定形甲磺酸奈非那韦的药物剂型 |
| MX2007003731A (es) | 2004-09-29 | 2007-08-14 | Johnson & Johnson | Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables. |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| TWI720517B (zh) | 2009-01-15 | 2021-03-01 | 美商英塞特公司 | 製造ｊａｋ抑制劑之方法及相關中間化合物 |
| HRP20250965T1 (hr) | 2012-06-15 | 2025-10-10 | Sun Pharmaceutical Industries, Inc. | Deuterirani derivati ruksolitiniba |
| ES2988629T3 (es) * | 2016-05-04 | 2024-11-21 | Sun Pharmaceutical Ind Inc | Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados |
| AU2020219797B2 (en) | 2019-02-06 | 2025-10-16 | Sun Pharmaceutical Industries, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| CA3228505A1 (en) * | 2021-08-11 | 2023-02-16 | Sun Pharmaceutical Industries, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
-
2021
- 2021-10-28 AU AU2021372512A patent/AU2021372512A1/en active Pending
- 2021-10-28 US US18/033,730 patent/US20230390292A1/en active Pending
- 2021-10-28 CA CA3196551A patent/CA3196551A1/en active Pending
- 2021-10-28 IL IL302401A patent/IL302401A/en unknown
- 2021-10-28 PE PE2023001507A patent/PE20231945A1/es unknown
- 2021-10-28 EP EP21811647.3A patent/EP4236956A1/en active Pending
- 2021-10-28 WO PCT/US2021/057123 patent/WO2022094133A1/en not_active Ceased
- 2021-10-28 MX MX2023005027A patent/MX2023005027A/es unknown
- 2021-10-28 KR KR1020237017998A patent/KR20230093504A/ko active Pending
- 2021-10-28 JP JP2023526173A patent/JP2023553253A/ja active Pending
-
2023
- 2023-04-26 CL CL2023001201A patent/CL2023001201A1/es unknown
- 2023-04-27 JO JOJO/P/2023/0090A patent/JOP20230090A1/ar unknown
- 2023-04-28 DO DO2023000085A patent/DOP2023000085A/es unknown
- 2023-05-25 CO CONC2023/0006808A patent/CO2023006808A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023001201A1 (es) | 2023-11-17 |
| US20230390292A1 (en) | 2023-12-07 |
| JOP20230090A1 (ar) | 2023-04-27 |
| MX2023005027A (es) | 2023-07-31 |
| CA3196551A1 (en) | 2022-05-05 |
| IL302401A (en) | 2023-06-01 |
| PE20231945A1 (es) | 2023-12-05 |
| AU2021372512A1 (en) | 2023-06-22 |
| KR20230093504A (ko) | 2023-06-27 |
| JP2023553253A (ja) | 2023-12-21 |
| EP4236956A1 (en) | 2023-09-06 |
| WO2022094133A9 (en) | 2023-05-19 |
| WO2022094133A1 (en) | 2022-05-05 |
| DOP2023000085A (es) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023006808A2 (es) | Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados | |
| MX2018013347A (es) | Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CL2021001951A1 (es) | Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los desordenes asociados a la edad. | |
| MX2021009269A (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| DOP2024000146A (es) | Inhibidores de parp7 | |
| CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| PE20241326A1 (es) | Composiciones y tratamientos con nirogacestat | |
| MX2025007935A (es) | Nuevos inhibidores reversibles de dpp1 y usos de estos | |
| MX2025013118A (es) | Tratamiento combinado para una enfermedad o un trastorno relacionado con ras | |
| DOP2025000009A (es) | Inhibidores de acc novedosos | |
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| MX2024003258A (es) | Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| MX2025014866A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos | |
| MX2025006279A (es) | Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a | |
| AR131842A1 (es) | Métodos para tratar gliomas | |
| MX2023013514A (es) | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. | |
| CL2025000332A1 (es) | Tratamiento de la urticaria con inhibidores de jak. | |
| MX2023011686A (es) | Metodos de tratamiento de la enfermedad de coronavirus y compuestos para los mismos. | |
| AR132852A1 (es) | Combiterapia para tratar el cáncer | |
| MX2024013641A (es) | Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak | |
| AR121415A1 (es) | INHIBIDORES DE LA QUINASA p38 QUE REDUCEN LA EXPRESIÓN DE DUX4 Y DE LOS GENES CORRIENTE ABAJO PARA USO EN EL TRATAMIENTO DE FSHD |